1Asadullah K,Sabat R.Wiese A,et al.Interleukin-10 in cutaneous disorders:implications for its pathophysiological importance and therapeutic use.Arch Dermalol Res.1999.291(12):628-636.
2Farkas A,Kemeny L.Szony BJ,et al.Dithranol upregulates IL-10 receptors on the cultured human keratinocyte cell line HaCaT.Inflamm Res.2001,50(1):44-49.
3Asadullah K,Sterry W.Stephanek K,et al.IL-10 is a key cytokine in psoriasis.Proof of principle by IL-10 therapy:a bew therapeutic approach.J Clin Imest.1998.101(4):783-794.
4Seifert M,Sterry W,Effenberger E,et al.The antipsoriatic activity of IL-10 is rather caused by effects on peripheral blood cells than by a direct effect on human keratin ocytes.Arch Dennatol Res 2000.292(4):164-172.
5Terui T,Ozawa M.Tagami H.Role of neutrophils in induction of acute inflammation in T-cell-mediated immune dermatosis.psoriasis:a neutrophil-associated inflammation-boosting loop.Exp Denostol 2000,9(1):1-10.
6Nickoloff BJ,Characterization of lymphocyte-dependent angiogenesis using a SCID mouse:human skin model of psoriasis,J Investig Dermatol Symp Proc,2000.5(1):67-73.
7Bonifati C,Mussi A.Carducci M,et al.Endothelin-1 levels are increased in sera and lesional skin extracts of psoriatic patients and correlate with disease severity Acta Derm Venereol.1998.78(1):22-26.
8Heng.MC.Song MK.Harker J.et al.Drug-induced suppression of phosphorylase kinase activity correlates with resohtion of psoriasis as assessed by clinical,histological and immunohistochemical parameters.Br J Dermatol 2000.143(5):937-949.
9Skov L.Baadsgaard O.Bacterial superantigens and inflammatory skin diseases.Clin Exp Dermatol.2000,25(1):57-61.
10Prinz JC.Which T cells cause psoriasis?Clin Exp Dermatol.1999.24(4):291-295.
